UTS spin-out Auspherix is hoping the collaboration will lead to a clinical drug candidate.
Auspherix, a spin-out of University of Technology Sydney (UTS), is entering a collaboration agreement with Domainex, an England-based drug discovery company. The aim of the partnership is to develop a clinical drug candidate based on Auspherix’s technology.
Auspherix, which has developed an anti-infective drug discovery programme, was spun in 2013. Its technology could allow the development of antibiotics capable of treating resistant bacterial diseases.
The company was founded by Ian Charles, director of the university’s ithree institute, and Dagmar Alber, senior…
